Commenting on the £400,000 that was secured from angel investment, alongside other sources, Dr Clarke said: “Angel investment was chosen as a successful route for PBD Biotech’s specialised products. This was because of the specialist local networks of individuals knowledgeable about the industry, and who understood the international opportunity offered by the technology.
“There is an enormous need for a tool to better monitor and control TB and M. paratuberculosis infections in livestock and other animals, and as such there is an enormous value attachment for an accurate test like Actiphage®. In England alone, bovine TB costs taxpayers over £100 million every year.”
To read the full interview about PBD Biotech, please visit growthbusiness.co.uk